Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 300-page biotech filing while trying to gauge trial timelines and cash runway can feel impossible. Edgewise Therapeutics’ disclosures are packed with sarcomere science, FDA designations and dilution math that most readers scroll past. If you have ever wondered “How do I find Edgewise Therapeutics insider trading Form 4 transactions before the market reacts?”—this page solves that problem.
Stock Titan’s AI immediately translates every Edgewise Therapeutics annual report 10-K into plain language, flags the R&D burn rate and highlights sevasemten clinical milestones. Need today’s Edgewise Therapeutics Form 4 insider transactions real-time? They are here alongside AI-powered summaries that point out which executives bought shares ahead of data readouts. Our platform also delivers Edgewise Therapeutics quarterly earnings report 10-Q filing commentary, breaks down equity financing terms, and links each 8-K material events explained line-by-line—so you know when Phase 2 results hit EDGAR.
Use cases go beyond speed. Compare quarter-over-quarter R&D expense without leafing through footnotes, monitor Edgewise Therapeutics proxy statement executive compensation to see options tied to trial success, or dive into Edgewise Therapeutics earnings report filing analysis for cash runway projections. Whether you are understanding Edgewise Therapeutics SEC documents with AI for the first time or tracking Edgewise Therapeutics executive stock transactions Form 4 like a pro, our real-time alerts and expert context deliver the insights that move biotech portfolios.
Edgewise Therapeutics (Nasdaq:EWTX) filed an 8-K furnishing upbeat interim data on sevasemten for Becker and Duchenne muscular dystrophies and summarizing recent FDA guidance.
- MESA extension (n = 85): 0.8-point NSAA improvement over 18 months, 3-year disease stabilization and 99 % rollover from prior studies.
- Placebo switchers gained 0.2 NSAA points.
- Safety remains favorable after up to three years.
- FDA confirmed NSAA as a meaningful endpoint and indicated the ongoing GRAND CANYON study (topline Q4 2026) could be a single pivotal trial for Becker registration.
- Duchenne Phase 2 LYNX & FOX: Well-tolerated across doses; 10 mg selected for Phase 3 after functional and biomarker benefits.
Management plans a Phase 3 design meeting with FDA in Q4 2025 and expects pivotal Duchenne enrollment in 2026. No financial metrics were disclosed.
Form 4 Filing Details: Laura Brege, Director of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The transaction involves the following key details:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of: - June 16, 2026 - Day before 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The filing was submitted by John R. Moore as attorney-in-fact for Laura Brege on June 18, 2025.
Edgewise Therapeutics (EWTX) director Badreddin Edris received a stock option grant for 30,000 shares of common stock on June 16, 2025. The options were granted with an exercise price of $14.68 per share.
Key terms of the stock option grant:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership form: Direct
The Form 4 was filed by attorney-in-fact John R. Moore on behalf of Badreddin Edris on June 18, 2025, within the required two-business-day filing window following the transaction.
Edgewise Therapeutics director Jonathan C. Fox received a stock option grant on June 16, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents a standard annual director compensation award. The filing was signed by John R. Moore as attorney-in-fact for Fox on June 18, 2025. The reporting person maintains direct ownership of these derivative securities.
Edgewise Therapeutics Director Arlene Morris received a stock option grant on June 16, 2025, representing a significant insider transaction. The key details of this Form 4 filing include:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule aligns with typical board member equity compensation structures. The filing was completed by Attorney-in-Fact John R. Moore on June 18, 2025.
Edgewise Therapeutics (EWTX) reported a Form 4 filing disclosing insider trading activity by Director Jonathan D. Root. On June 16, 2025, Root was granted 30,000 stock options with the following key terms:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership type: Direct
The stock options represent the right to purchase 30,000 shares of Edgewise Therapeutics common stock. The transaction was executed under standard compensation arrangements for directors, with zero cost basis for the options grant. The filing was completed by John R. Moore as attorney-in-fact for Jonathan Root on June 18, 2025.
Peter A. Thompson, who serves as both Director and 10% Owner of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest 100% on the earlier of:
- June 16, 2026, or
- The business day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
The transaction was reported via Form 4 filing, signed by John R. Moore as attorney-in-fact for Peter Thompson on June 18, 2025. This equity compensation grant aligns with standard director compensation practices and represents a long-term incentive structure with a one-year cliff vesting period.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
What is the primary focus of Edgewise Therapeutics, Inc.?
Which therapeutic areas does the company target?
How does Edgewise Therapeutics generate its revenue?
What distinguishes Edgewise Therapeutics from its competitors?
In which stage of drug development is the company currently involved?
Where is Edgewise Therapeutics headquartered?
Can you explain the significance of orally bioavailable therapies in Edgewise Therapeutics' approach?
